Prof. Frank Tacke

Prof. Frank Tacke

Frank Tacke was originally educated at the medical school in Hannover, Germany, and Baylor College of Medicine, Houston, TX. Later he stayed at University of Texas, M.D. Anderson Cancer Center in Houston, working on new gene therapy strategies (1998-1999) as well as for a post-doctoral research training (2004-2006) at the Mount Sinai Medical Center, New York, working on monocyte/macrophage and dendritic cell biology. Since 2006, he is a clinical physician and leader of a research laboratory at the University Hospital Aachen, Germany.

He is board-certified in Internal Medicine, Gastroenterology and Critical Care Medicine. His research interests are: Clinical and Experimental Hepatology, Liver Immunology, Viral Hepatitis, Gastroenterology, Critical Care Medicine, and Monocyte/Macrophage Biology. In 2012, Frank Tacke was appointed as an Associate Professor (W2-professorship) at the RWTH University Aachen. He has (co‑)authored >180 peer-reviewed original and review articles.

Prof. F. Tacke

Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany

As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.
Read More
Prof. F. Tacke

The multiple risks in NAFLD by Prof. F. Tacke

In NAFLD, the liver is both victim and motor of a multisystem disease. Liver disease is not limited to the liver itself but has an impact on glycemic control in the body. Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies.
Read More

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES